Damora Therapeutics, Inc.
DMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDamora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company carries a $1.86B market cap, placing it firmly in the small-cap category. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Market Cap
$1.86B
Beta
1.47
P/E (TTM)
—
P/E (Fwd)
-14.03
EPS (TTM)
$-0.26
EPS (Fwd)
$-2.14
ROE
-99.7%
ROA
-21.6%
Cash
$540.5M
Total Debt
$0
Free CF
-$16.0M
52W Change
1065.1%
Annual Financials
Cash vs Debt
Where DMRA stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, DMRA finished 14.64% above its 150-day moving average ($26.44) and 18.72% above its 200-day moving average ($25.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMRA overbought or oversold?
At the August 25, 2026 close, DMRA's RSI(14) was 51.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Damora Therapeutics, Inc. reports $540.5M in cash and $0 in total debt. Free cash flow is running at -$16.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -99.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Damora Therapeutics, Inc.'s trajectory.